Cargando…
Blood biomarkers as surrogate endpoints of treatment responses to aerobic exercise and cognitive training (ACT) in amnestic mild cognitive impairment: the blood biomarkers study protocol of a randomized controlled trial (the ACT Trial)
BACKGROUND: Alzheimer’s disease (AD) is an epidemic with tremendous public health impacts because there are currently no disease-modifying therapeutics. Randomized controlled trials (RCTs) for prevention of AD dementia often use clinical endpoints that take years to manifest (e.g., cognition) or sur...
Autores principales: | Li, Danni, Mielke, Michelle M., Bell, W. Robert, Reilly, Cavan, Zhang, Lin, Lin, Feng Vankee, Yu, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943901/ https://www.ncbi.nlm.nih.gov/pubmed/31907024 http://dx.doi.org/10.1186/s13063-019-3798-1 |
Ejemplares similares
-
Efficacy and mechanisms of combined aerobic exercise and cognitive training in mild cognitive impairment: study protocol of the ACT trial
por: Yu, Fang, et al.
Publicado: (2018) -
Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
por: Insel, Philip S, et al.
Publicado: (2015) -
Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002) -
Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers
por: Morel, Alix, et al.
Publicado: (2021) -
Biomarkers and Surrogate Endpoints: Lessons Learned From Glaucoma
por: Medeiros, Felipe A.
Publicado: (2017)